A randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial to assess the safety and efficacy of ciclesonide, applied as a nasal spray (200microg once daily) in the treatment of seasonal allergic rhinitis (SAR) in patients 12 years and older.
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2016
At a glance
- Drugs Ciclesonide (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors ALTANA Pharma; AstraZeneca
- 09 May 2008 New trial record.